How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

502,070 results for

(respiratory or pulmonary or lung or asthma or asthmatic or breathing)

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis

Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 8 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA. 9 Turku University Hospital and University of Turku, Turku, Finland. 10 Brigham and Women's Hospital Heart and Vascular Center, and Harvard Medical School, Boston, MA, USA; Turku University Hospital and University (...) of Turku, Turku, Finland. 11 Division of Cardiology, Pôle Coeur Thorax Vasculaire, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine de l'Université François Rabelais, Tours, France. 12 Department of Cardiology, Bern University Hospital, Bern, Switzerland. 13 Hospital General Universitario de Alicante, Alicante, Spain. 14 Department of Hypertension, Medical University of Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. 15 Centro Nacional de

2020 EvidenceUpdates

142. Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock

and Critical Care, Department of Medicine, University of Southern California, Los Angeles, CA. 18 Department of Critical Care, Respiratory Institute, Cleveland Clinic, Cleveland, OH. 19 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Intermountain Healthcare, Salt Lake City, UT. 20 Division of Critical Care Medicine, Department of Anesthesiology, Duke University School of Medicine, Durham, NC. 21 Division of Critical Care, St Agnes Hospital, Baltimore, MD. 22 Division (...) , Cincinnati, OH. 16 Department of Emergency Medicine, University of Rochester Medical Center, Rochester, NY. 17 Division of Pulmonary and Critical Care, Department of Medicine, University of Southern California, Los Angeles, CA. 18 Department of Critical Care, Respiratory Institute, Cleveland Clinic, Cleveland, OH. 19 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Intermountain Healthcare, Salt Lake City, UT. 20 Division of Critical Care Medicine, Department of Anesthesiology

2020 EvidenceUpdates

143. Safety of using the combination of the Wells rule and D-dimer test for excluding acute recurrent ipsilateral deep vein thrombosis Full Text available with Trip Pro

Dermatol. 2013. PMID: 24192389 Clinical Trial. Show more similar articles References REFERENCES Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e351S-e418S. Barco S, Konstantinides S, Huisman MV, Klok FA. Diagnosis of recurrent venous thromboembolism. Thromb Res. 2018;163:229-235. Huisman MV, Klok FA. Diagnostic management of acute (...) deep vein thrombosis and pulmonary embolism. J Thromb Haemost. 2013;11(3):412-422. Tan M, van Rooden CJ, Westerbeek RE, Huisman MV. Diagnostic management of clinically suspected acute deep vein thrombosis. Br J Haematol. 2009;146(4):347-360. Tan M, Velthuis SI, Westerbeek RE, Van rooden CJ, Van der meer FJM, Huisman MV. High percentage of non-diagnostic compression ultrasonography results and the diagnosis of ipsilateral recurrent proximal deep vein thrombosis. J Thromb Haemost. 2010;8(4):848-850

2020 EvidenceUpdates

144. Clinical Performance Measures for Neurocritical Care

. Antithrombotic and thrombolytic therapy for ischemic stroke: the seventh ACCP confer- ence on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):483S–512S. 14. Albers GW, Amarenco P , Easton JD, Sacco RL, Teal P . Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):630S–69S. 15. Alonso de Lecinana M, Egido JA, Casado I, et al. Guidelines for the treat- ment of acute

2020 Neurocritical Care Society

145. Lifelight First for monitoring vital signs

the introduction of the Quality and Outcome Framework in 2014, GPs review people with some common chronic conditions such as asthma, diabetes, obesity and hypertension on a regular basis. This involves monitoring any change in blood pressures, pulse and respiratory rates. In current practice, contact-based methods are used to measure these, but such methods may not be tolerated by some patients and may cause distress, and in some cases needs personal protective equipment to prevent cross-contamination (...) . These studies show that the accuracy of Lifelight First is similar to some clinical-grade monitoring devices when compared with the Welch Allyn Connex Monitor for measuring heart rate, blood pressure and manual counting for measuring respiratory rate. • Key uncertainties Key uncertainties around the evidence or technology are that the evidence base does not evaluate the technology in a clinically relevant population, including people that need routine monitoring of vital signs. The evidence is unpublished

2020 NICE COVID-19 rapid evidence summary

146. myCOPD for self-management of chronic obstructive pulmonary disease

relevant information about their condition in one place. People would be able to access information and services (such as pulmonary rehabilitation) in their own homes. Potential patient impact Potential patient impact The main benefits identified by the expert commentators were improvements in self-management and education, and support for pulmonary rehabilitation. The technology offers training on inhaler technique and breathing control, helping people to manage their symptoms themselves. The experts (...) myCOPD for self-management of chronic obstructive pulmonary disease myCOPD for self-management of chronic obstructive pulmonary disease Medtech innovation briefing Published: 1 April 2020 www.nice.org.uk/guidance/mib214 pathways Summary Summary • The technology technology described in this briefing is myCOPD. It helps people with chronic obstructive pulmonary disease (COPD) to manage their symptoms and reduce the number of healthcare visits they need. It also helps the healthcare professionals

2020 NICE COVID-19 rapid evidence summary

147. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

exhibit a mild illness (80%+), 14% have serious and 5% have critical illness. Approximately 10% will require hospital admission due to COVID-19 pneumonia, of which approximately 10% will require ICU care, including invasive ventilation due to acute respiratory distress syndrome (ARDS) [3]. While mortality appears to be more common in older individuals and those with comorbidities, such as chronic lung disease, cardiovascular disease, and diabetes, young people with no comorbidities also appear (...) of MERS-CoV and improve lung pathology in a nonhuman primate model of common marmoset [42]. Lopinavir/ritonavir and interferon-ß1b alone or in combination are being evaluated in clinical trials. COVID-19 convalescent plasma for prophylaxis There is a long history of using convalescent plasma as treatment for infectious diseases, including severe viral lower respiratory tract infections [43]. Individuals who have recovered from SARS-CoV-2 infection may generate neutralizing antibodies [44, 45

2020 Infectious Diseases Society of America

148. Guidance for the role and use of non-invasive respiratory support in adult patients with COVID-19 (suspected or confirmed)

• The use of HFNO is not advocated in COVID-19 patients based on lack of efficacy, oxygen use and infection spread. • NIV with BiPAP is usually not needed in those with otherwise normal lungs; compliance is usually maintained in COVID-19 patients. However, excessive work of breathing is a possible indicator for intubation. The use of NIV (BiPAP) should be reserved for those with hypercapnic acute on chronic ventilatory failure. • CPAP is the preferred form of non-invasive ventilatory support (...) can be distressing for patients, and the use of low doses of agents to improve comfort and tolerance can be considered. Opioids, in appropriate and judicious doses, may help reduce the sensation of breathlessness and also limit very high tidal volumes and respiratory rates – which are thought likely to be driving ongoing patient-induced lung injury (PILI). • Cohorting of these patients can be considered, but it is essential that strict care is taken with other hygiene precautions. The risk

2020 British Thoracic Society

149. SIR Position Statement on Thermal Ablation for the Treatment of Renal Cell Carcinoma Full Text available with Trip Pro

, A. et al. Epidemiology of renal cell carcinoma. Eur Urol . 2019 ; 75 : 74–84 | | | | | 6 , x 43 Choueiri, T.K. and Motzer, R.J. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med . 2017 ; 376 : 354–366 | | | 43 ). Distant metastases occur most frequently in the lungs, lymph nodes, liver, bone, and brain ( x 43 Choueiri, T.K. and Motzer, R.J. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med . 2017 ; 376 : 354–366 | | | 43 ). Surgical metastasectomy as a treatment (...) RCC. Bang et al ( x 45 Bang, H.J., Littrup, P.J., Goodrich, D.J. et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol . 2012 ; 23 : 770–777 | | | | | 45 ) assessed the role of multisite cryoablation of oligometastatic RCC on local recurrence and survival. A total of 27 patients (with 72 tumors) were included in the study with procedural sites including the lung

2020 Society of Interventional Radiology

150. 2020 Atrial Fibrillation (Management of) Guidelines

disease, Age 65–74 years, Sex category (female) CHADS 2 CHF history, Hypertension history, Age ≥75 y, Diabetes mellitus history, Stroke or TIA symptoms previously CHF Congestive heart failure CI Confidence interval CIED Cardiac implantable electronic device CKD Chronic kidney disease COP-AF Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery COPD Chronic obstructive pulmonary disease CPAP Continuous positive airway pressure CrCl Creatinine (...) 2020 Atrial Fibrillation (Management of) Guidelines 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) | European Heart Journal | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Navbar Search Filter Mobile Microsite Search Term

2020 European Society of Cardiology

151. 2020 Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation (Management of) Guidelines Full Text available with Trip Pro

with cardiomyocyte injury (= cardiac troponin elevation) 13 Table 5 Assay specific cut-off levels in ng/l within the 0 h/1 h and 0 h/2 h algorithms 15 Table 6 Differential diagnoses of acute coronary syndromes in the setting of acute chest pain 18 Table 7 Major andminor criteria for high bleeding risk according to the Academic Research Consortium for High Bleeding Risk at the time of percutaneous coronary intervention (bleeding risk is high if at least one major or two minor criteria aremet) 21 Table 8 Dose (...) -Thoracic Surgery ECG Electrocardiogram/electrocardiography Echo Echocardiogram eGFR Estimated glomerular filtration rate ELISA Early or Late Intervention in unStable Angina ENTRUST- AF PCI EdoxabaN TRreatment versUS VKA in paTients with AF undergoing PCI ESC European Society of Cardiology FAMOUS- NSTEMI Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction FFR Fractional flow reserve FFR-CT Fractional flow reserve-computed

2020 European Society of Cardiology

152. National Practice Guideline For the Treatment of Opioid Use Disorder

types of public sector clinics that can be authorized to prescribe the partial opioid agonist buprenorphine in outpatient settings. There is no regulation, per se, of the clinic site itself, but of the individual clinician who prescribes buprenorphine. Opiate: One of a group of alkaloids derived from the opium poppy(Papaversomniferum), with the ability to induce analgesia, euphoria, and, in higher doses, stupor, coma, and respiratory depression. The term excludes synthetic opioids. Opioid: A current

2020 Publication 4891078

153. Considerations for Reduction of Risk of Perioperative Stroke in Adult Patients Undergoing Cardiac and Thoracic Aortic Operations: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Considerations for Reduction of Risk of Perioperative Stroke in Adult Patients Undergoing Cardiac and Thoracic Aortic Operations: A Scientific Statement From the American Heart Association Considerations for Reduction of Risk of Perioperative Stroke in Adult Patients Undergoing Cardiac and Thoracic Aortic Operations: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search September (...) 2020 August 2020 July 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article Share on Jump to Free Access Review Article Considerations for Reduction of Risk of Perioperative Stroke in Adult Patients Undergoing Cardiac and Thoracic Aortic Operations: A Scientific Statement From the American Heart Association , MD, Chair , MD, MPH, Vice Chair , MD , MD, FAHA

2020 American Heart Association

154. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2 Full Text available with Trip Pro

below to share a full-text version of this article with your friends and colleagues. Copy URL Share a link Share on . Caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS–CoV‐2), COVID‐19 has impacted millions of lives and has contributed to a growing number of deaths worldwide. The pandemic poses a substantial challenge for both rheumatology providers and patients since serious infection is a well‐recognized cause of morbidity and mortality across a number of rheumatic (...) SARS–CoV‐2 exposure (Table 5), and 5) rheumatic disease treatment in the context of documented or presumptive COVID‐19 (Table 5). Table 2. General guidance for patients with rheumatic disease a COVID‐19 = coronavirus disease 2019; SARS–CoV‐2 = severe acute respiratory syndrome coronavirus 2; ACE = angiotensin‐converting enzyme; ARB = angiotensin receptor blocker. Guidance statement Level of task force consensus The risk of poor outcomes from COVID‐19 appears to be related primarily to general risk

2020 American College of Rheumatology

155. Clinical Guidance Summary for Pediatric Patients with MIS-C Associated with SARS-CoV-2 and Hyperinflammation in COVID-19

The Task Force was convened by the ACR to provide guidance on the management of inflammatory syndromes in children (up to age 18) with recent or concurrent infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This document addresses Multisystem Inflammatory Syndrome in Children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of SARS-CoV-2 infection. Notably, the Task Force did not attempt to create a case (...) explain the clinical presentation (H). • See Figure 1 for guidance on the diagnostic evaluation of MIS-C (M/H). 2 • Patients under investigation for MIS-C may require additional diagnostic studies (not described in Figure 1) including but not limited to imaging of the chest, abdomen, and/or central nervous system and lumbar puncture (H). • Outpatient evaluation for MIS-C may be appropriate for well appearing children with stable vital signs and reassuring physical exams provided close clinical follow

2020 American College of Rheumatology

156. Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG) (includes supplemental material)

with snoring and sleep apnea, and wheezing is noted due to obstructive pulmonary disease. Cardiac disease leading to congestive heart failure occurs from both valve thickening leading to regurgitation and stenosis, and myocardial dysfunction secondary to infiltration with GAGs. Death occurs from the cardiac or pulmonary disease in most by 10 to 15 years of age. 5 There is a broad spectrum of MPS II from the typical severe form to an attenuated or very mild form, with significant heterogeneity between (...) on pulmonary function tests (PFT). 10,11 Early evidence from the Hunter Outcome Survey suggest life span may be increased by ERT. 12 Controlled trials of idursulfase have not been conducted on individuals with severe MPS II. Despite the lack of known therapeutic efficacy, individuals with severe MPS II have been treated with ERT. Small case series reporting ERT for the severe form of the disease seem to confirm benefits for reduction in liver and spleen volumes, joint range of motion, and possibly improved

2020 American College of Medical Genetics and Genomics

157. The risk of bleeding and all-cause mortality with edoxaban versus vitamin K antagonists: A meta-analysis of phase III randomized controlled trials

-cause mortality in patients with edoxaban versus VKAs were included in our meta-analysis. Both random- and fixed-effects models were used to pool data across phase III RCTs. Results: We included four trials that met our inclusion criteria (n = 33,077). They included patients with atrial fibrillation (3 trials, n = 24,847), venous thromboembolism (VTE) or pulmonary embolism (PE) (1 trial, n = 8240). Edoxaban was associated with reduced risks of major or clinically relevant nonmajor bleeding (CRNM

2020 EvidenceUpdates

158. Early surgery versus conservative management of asymptomatic severe aortic stenosis: A meta-analysis

at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Thorac Cardiovasc Surg Actions . 2020 Jul 5;S0022-5223(20)31984-X. doi: 10.1016/j.jtcvs.2020.06.078. Online ahead of print. Early surgery versus conservative (...) of asymptomatic severe aortic stenosis: A meta-analysis Yujiro Yokoyama et al. J Thorac Cardiovasc Surg . 2020 . Show details Display options Display options Format J Thorac Cardiovasc Surg Actions . 2020 Jul 5;S0022-5223(20)31984-X. doi: 10.1016/j.jtcvs.2020.06.078. Online ahead of print. Authors , , Affiliations 1 Department of Surgery, St. Luke's University Health Network, Bethlehem, Pa. 2 Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan. 3 Department of Medicine, Icahn School

2020 EvidenceUpdates

159. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Full Text available with Trip Pro

University, and CIBER CV, Avenida Reyes Católicos 2, 28040 Madrid, Spain. 2 Department of Cardiology, Université de Paris, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Université de Paris, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, Paris, France. 3 National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK. 4 Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 5 Division of Cardiovascular Disease, University of Alabama (...) . 2020 Aug 21;ehaa498. doi: 10.1093/eurheartj/ehaa498. Online ahead of print. Authors , , , , , , , , , , , , , , , , , Affiliations 1 Division of Cardiology, Fundación Jiménez Díaz, Autónoma University, and CIBER CV, Avenida Reyes Católicos 2, 28040 Madrid, Spain. 2 Department of Cardiology, Université de Paris, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Université de Paris, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, Paris, France. 3 National Heart and Lung Institute

2020 EvidenceUpdates

160. Pectoral block versus paravertebral block: a systematic review, meta-analysis and trial sequential analysis

-text links Cite Display options Display options Format Abstract Background: Pectoral (PECs) block was first described by Blanco et al for postoperative analgesia in breast surgery. It was proposed to be an easier and safer alternative to thoracic epidural or paravertebral block (PVB). In this systematic review and meta-analysis, we compare the perioperative analgesic efficacy and adverse events of PECs block and PVB. Methods: We systematically searched PubMed, Central, EMBASE, CINAHL, Google

2020 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>